ソース:[1] ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) | Seeking Alpha (https://seekingalpha.com/article/4828005-acad ...)[2] Shareholder Risk and Corporate Governance at ACADIA Pharmaceuticals: Legal Scrutiny and Investor Confidence in the Wake of ACP-101's Failure - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview (https://vertexaisearch.cloud.google.com/groun ...)